罗格列酮对大鼠系膜增生性肾炎的治疗作用  

Therapeutic effects of rosiglitazone on mesangial proliferative glomerulonephritis in rats

作　　者：刘健胜[1] 沈琪[1] 卢思广[1] 

机构地区：[1]江苏省连云港市第一人民医院儿科,江苏连云港222002

出　　处：《临床儿科杂志》2009年第4期321-325,共5页Journal of Clinical Pediatrics

摘　　要：目的研究罗格列酮对大鼠系膜增生性肾炎(MsPGN)的治疗作用并探讨其可能的作用机制,寻找治疗系膜增生性肾炎的新途径。方法大鼠随机分为3组:空白对照组(A组)、模型对照组(B组)、罗格列酮治疗组(C组)。B、C组以四氯化碳及牛血清白蛋白灌胃制备系膜增生性肾炎模型,制模成功后,A、B组予生理盐水,治疗组予罗格列酮分别灌胃均8周,每周测各组大鼠24 h尿蛋白排泄量及尿红细胞计数。实验结束时,测血清白蛋白、血糖、肝肾功能、肾脏系膜细胞及系膜基质增生情况(光镜、PAS染色)及各组大鼠肾脏转化生长因子-β1(TGF-β1)、α-平滑肌肌动蛋白(α-SMA)表达水平。结果治疗组大鼠24 h尿蛋白排泄量、尿红细胞计数、TGF-β1及α-SMA表达水平、肾小球PAS染色灰度值较模型组均明显减少,血清白蛋白明显升高,差异均有统计学意义。3组之间血糖及肝肾功能比较差异无统计学意义。结论罗格列酮对大鼠系膜增生性肾炎具有治疗作用,其作用机制之一可能是通过抑制TGF-β1及其下游因子表达。Objective To investigate the therapeutic effects and possible mechanisms of rosiglitazone on mesangial proliferative glomerulonephritis （MsPGN） and to search a new therapeutic method on treatment of MsPGN. Methods Rats were randomly divided into three groups. A, a blank control group （control group） ; B,a model group （model group） ; C, a model group treated with rosiglitazone （treated group）. Rats in B and C groups were induced into MsPGN animal model. After successful setup of the animal model, rosiglitazone was continually infused into the stomach of C group for 8 weeks. The protein in 24 h urine, urine red blood cell count, serum albumin, blood glucose, aspartate aminotransferase （AST）, serum alanine aminotransferase （ALT）, blood urea nitrogen （BUN）, serum creatinine （sCr）, BUN/sCr ratio, the expression of transforming growth factor-betal （TGF-β1） and a-smooth muscle actin （α-SMA） and accumulation of PAS-positive material in glomeruli were examined. Results Compared with model groups, protein in 24 h urine, urine red blood cell count, expression of TGF-β1, α-SMA, and accumulation of PAS-positive material in glomeruli in treated group were significantly decreased. The level of serum albumin was significantly increased in treated group than in model group. There were no statistically significant differences in blood glucose, AST, ALT, BUN, sCr. Conclusions Rosiglitazone has therapeutic effects on mesangial proliferative glomerulonephritis in rats and are of the mechanism may be inhibition of the expression of TGF-β1 and its downstream factors.

关 键 词：系膜增生性肾炎 罗格列酮 尿红细胞 24 h尿蛋白定量 转化生长因子-β1 Α-平滑肌肌动蛋白 

分 类 号：R96[医药卫生—药理学]